Doubt has been cast over the current practice of administering intensive insulin therapy to all critically ill patients, according to a study published this week in the open access journal Critical Care. In certain groups of patients it could even be harmful.
This therapy is used widely in hospitals around the world, yet only one randomised, controlled trial showing unequivocal benefit has been published – and this trial focused mainly on patients who had undergone cardiac surgery. So, a team from Harborview Medical Center and the University of Washington, Seattle, set out to explore the relationship between intensive insulin therapy and hospital mortality in a mixed population of critically ill patients.
The researchers examined the outcomes of all (10,456) patients admitted to the seven intensive care units (ICUs) of Harborview Medical Center, the only Level 1 trauma center in a 5 state area of the northwest USA, before and after the introduction of intensive insulin protocols. The study period (March 2001 to February 2005) was split into three consecutive sections: Period I (no specific glycemic control protocol), Period II (target glucose 80–130mg/dL) and Period III (target glucose 80–110mg/dL). The study population included a mix of trauma, surgical, neurosurgical and medical ICU patients.
They found that a policy of intensive insulin therapy was not associated with a decrease in hospital mortality. While the proportion of patients receiving insulin infusions increased from 9% in Period I to 42% in Period III, patients in Period III tended towards higher hospital mortality than those in Period I. Hospital mortality was increased in patients with an ICU stay of three days or less.
The authors suggest that further study is necessary before intensive insulin therapy is implemented widely in critically ill patients.
They write: “We observed that intensive insulin therapy in a mixed cohort of critically ill patients was not associated with a reduction in hospital mortality, and was associated with increased ICU and hospital mortality in some subgroups. “These results, combined with data from the most recently concluded randomised trials, suggest that broad implementation of intensive insulin therapy may be premature, and that additional randomised trials in diverse groups of critically ill patients are necessary.”
Source: BioMed Central
Related stories:
Having heart surgery? Watch your blood sugar, especially if you're overweight or older
Nearly half of all heart surgery patients may experience blood sugar levels high enough to require temporary insulin treatment after their operation, even though they've never had diabetes, according to a new study from the University of Michigan Health System.
Researchers aim to improve asthma patients' care through computer-based simulation program
Mayo Clinic pulmonary researchers have designed and tested a new patient education computer program intended to help people with asthma manage their disease. The program allows asthma patients (an estimated 7 percent of the U.S. adult population) to practice making key decisions in a safe, simulated environment.
Studies test new approaches to islet transplantation
Researchers from 11 medical centers in the United States, Canada, Sweden, and Norway have begun testing new approaches to transplanting clusters of insulin-producing islets in adults with difficult-to-control type 1 diabetes. The clinical studies, funded by the National Institutes of Health (NIH), will determine whether changes to current methods of islet transplantation lead to improved, long-lasting control of blood glucose with fewer side effects.
Weight loss more effective than intensive insulin therapy for type 2 diabetics
Weight-loss and major lifestyle changes may be more effective than intensive insulin therapy for overweight patients with poorly controlled, insulin-resistant type 2 diabetes, according to a diabetes researcher at UT Southwestern Medical Center.
Intensive insulin therapy protects kidneys in critically ill patients
For critically ill patients, intensive insulin therapy (IIT) to keep blood sugar (glucose) at normal levels reduces the risk of acute kidney injury, reports a study in the March Journal of the American Society of Nephrology.
Landmark trial to evaluate cardioprotective properties of insulin
The ability of insulin to limit heart-tissue damage during a heart attack will be tested in a landmark clinical trial led by Paresh Dandona, M.D., Ph.D., University at Buffalo Distinguished Professor in the departments of Medicine and Pharmacology and Toxicology in the UB School of Medicine and Biomedical Sciences.
For some diabetics, burden of care rivals complications of disease
Many patients with diabetes say that the inconvenience and discomfort of constant therapeutic vigilance, particularly multiple daily insulin injections, has as much impact on their quality of life as the burden of intermediate complications, researchers from the University of Chicago report in the October 2007 issue of
Diabetes Care.
Silver is the key to reducing pneumonia associated with breathing tubes
People have long prized silver as a precious metal. Now, silver-coated endotracheal tubes are giving critically ill patients another reason to value the lustrous metal. In a study published in the Aug. 20, 2008 issue of the
Journal of the American Medical Association, researchers at Washington University School of Medicine in St. Louis and the NASCENT Investigation Group, report that the silver-coated tubes led to a 36 percent reduction of ventilator-associated pneumonia (VAP).